Vivi Julietta

Ms. Vivi Julietta

Indonesia International Institute for Life Sciences, Jakarta, Indonesia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
MGMarsia Gustiananda
Marsia Gustiananda
VJVivi Julietta
Vivi Julietta
AHAngelika Hermawan
Angelika Hermawan
GFGabriella Gita Febriana
Gabriella Gita Febriana
RHRio Hermantara
Rio Hermantara
Arli Aditya ParikesitArli Aditya Parikesit
Arli Aditya Parikesit
Reports on T-cell cross-reactivity against SARS-CoV-2 epitopes in unexposed individuals have been linked with prior exposure to the human common cold coronaviruses (HCCCs). Several studies suggested that cross-reactive T-cells response to live attenuated vaccines (LAVs) such as BCG (Bacillus Calmette–Guérin), OPV (Oral Polio Vaccine), and MMR (measles, mumps, and rubella) can limit the development and severity of COVID-19. This study aims to identify potential cross-reactivity between SARS-CoV-2, HCCCs, and LAVs in the context of T-cell epitopes peptides presented by HLA (Human Leukocyte Antigen) alleles of the Indonesian population. SARS-CoV-2 derived T-cell epitopes were predicted using immunoinformatics tools and assessed for their conservancy, variability, and population coverage. Two fully conserved epitopes with 100% similarity and nine heterologous epitopes with identical T-cell receptor (TCR) contact residues were identified from the ORF1ab fragment of SARS-CoV-2 and all HCCCs. Cross-reactive epitopes from various proteins of SARS-CoV-2 and LAVs were also identified (15 epitopes from BCG, 7 epitopes from MMR, but none from OPV). A majority of the identified epitopes were observed to belong to ORF1ab, further suggesting the vital role of ORF1ab in the coronaviruses family and suggesting it as a candidate for a potential universal coronavirus vaccine that protects against severe disease by inducing cell mediated immunity.

31 October 2026 in Endocrinology and Metabolism
Verified
Journal Article
Open access
MSMihye Seo
Mihye Seo
MAMaria Averia
Maria Averia
VJVivi Julietta
Vivi Julietta
SSShindy Soedono
Shindy Soedono
EJEsther Jin Joo
Esther Jin Joo
KCKae Won Cho
Kae Won Cho
Background: Obesity is characterized by chronic inflammation and fibrosis of adipose tissue; however, the extent to which these pathological features persist during pharmacologically induced weight loss remains poorly understood. This study investigated the effects of tirzepatide, a dual agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, on adipose tissue inflammation and fibrosis in obese mice.Methods: Diet-induced obesity was treated with tirzepatide or vehicle for 25 days. Metabolic parameters, tissue inflammation, fibrosis, and macrophage activation were assessed using histology, flow cytometry, gene expression analyses, and immunoblotting. In vitro experiments were conducted to compare the effects of tirzepatide on classically activated and metabolically activated macrophages.Results: Tirzepatide significantly reduced body weight and adiposity, increased energy expenditure, and upregulated thermogenic and mitochondrial proteins in brown adipose tissue. Hyperglycemia and glucose intolerance were normalized. However, adipose tissue inflammation and fibrosis persisted despite weight loss, as evidenced by sustained immune cell infiltration, collagen deposition, and activation of Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) signaling. In contrast, hepatic inflammation and fibrosis were substantially improved. Mechanistically, tirzepatide suppressed inflammatory gene expression in classically activated macrophages but not in metabolically activated macrophages, suggesting that the local metabolic context determines tissue responsiveness to its anti-inflammatory actions.Conclusion: Tirzepatide exerts distinct tissue-specific effects on inflammation and fibrosis during weight loss, ameliorating hepatic pathology while sparing adipose tissue inflammation. These findings identify metabolically activated macrophages as potential determinants of tissue-specific inflammatory persistence and underscore the need for therapeutic strategies that target macrophage activation and fibrotic remodeling to achieve durable metabolic benefits during pharmacological weight loss.

1 January 2026 in CardioMetabolic Syndrome Journal
Verified
Journal Article
Open access
PDF file
SSShindy Soedono
Shindy Soedono
VJVivi Julietta
Vivi Julietta
EBEllen Budiono
Ellen Budiono
MAMaria Averia
Maria Averia
HNHadia Nawaz
Hadia Nawaz
KCKae Won Cho
Kae Won Cho
Soedono S, et al. Cardiometab Syndr J. 2026 ;6:e20. https://doi.org/10.51789/cmsj.2026.6.e20

22 October 2026 in Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
MSMihye Seo
Mihye Seo
VJVivi Julietta
Vivi Julietta
MAMaria Averia
Maria Averia
SSShindy Soedono
Shindy Soedono
EBEllen Budiono
Ellen Budiono
KCKae Won Cho
Kae Won Cho
Weight loss improves obesity-associated metabolic dysfunction, yet resolution of adipose inflammation may be incomplete and can reappear during weight regain. Whether high-dose semaglutide induces sustained immunological remodeling of adipose and hepatic tissues during weight cycling remains unclear. Male C57BL/6 mice with diet-induced obesity were treated with semaglutide (60 nmol/kg, intraperitoneally, every 3 days) or vehicle for 3 weeks, followed by drug withdrawal under continued high-fat diet feeding. Body weight, body composition, and glucose homeostasis were assessed during treatment and after weight regain. Inflammatory changes in visceral and subcutaneous adipose tissue and liver were analyzed by flow cytometry, histology, immunofluorescence, and gene expression profiling. Semaglutide induced rapid fat mass-selective weight loss with preservation of lean mass and significantly improved fasting glucose, insulin levels, insulin sensitivity, and glucose tolerance. During treatment, visceral adipose tissue exhibited marked reductions in pro-inflammatory macrophages, crown-like structures, and inflammatory gene expression, whereas subcutaneous adipose tissue was minimally affected. Following withdrawal, mice rapidly regained weight and adiposity. Visceral adipose inflammation fully reverted, with macrophage infiltration and inflammatory gene expression comparable to chronically obese controls. Hepatic steatosis and inflammatory markers similarly returned to obese levels. Despite this tissue-level reversion, fasting glycemia and insulin levels remained partially improved. High-dose semaglutide induces robust metabolic improvement and transient suppression of visceral adipose inflammation during active treatment; however, these inflammatory changes are not sustained after withdrawal and largely revert with weight regain. In contrast, partial improvement in fasting glycemia persisted, suggesting differential durability between systemic metabolic adaptation and local inflammatory remodeling during pharmacological weight cycling.